Suchergebnisse - "Oaknin, Ana"

PubPharm (165)

1

Immunotherapy in the treatment of advanced or recurrent endometrial cancer

enthalten in: Clinical advances in hematology & oncology : H&O | 2024

von Grau-Bejar, J. | Farinas-Madrid, L. | García-Duran, C. | +3

2

Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358) : a phase 1-2, open-label, multicohort trial

enthalten in: The Lancet. Oncology | 2024

von Oaknin, A. | Moore, K. | Meyer, T. | +17

3

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18) : a randomised, double-blind, phase 3 clinical trial

enthalten in: Lancet (London, England) | 2024

von Lorusso, D. | Xiang, Y. | Hasegawa, K. | +32

4

Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis

enthalten in: Cancer treatment reviews | 2024

von Bartoletti, M. | Montico, M. | Lorusso, D. | +6

5

Mirvetuximab soravtansine-gynx : first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2024

von Bogani, G. | Coleman, R. | Vergote, I. | +8

6

Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Oaknin, A. | Ghamande, S. | Kasamatsu, Y. | +8

7

The evolving landscape of antibody-drug conjugates in ovarian cancer : new drugs for a new era

enthalten in: Current opinion in obstetrics & gynecology | 2024

von García-Illescas, D. | Mazzeo, R. | García-Durán, C. | +1

8

Targeting HER2-mutant metastatic cervical cancer with neratinib : Final results from the phase 2 SUMMIT basket trial

enthalten in: Gynecologic oncology | 2024

von Friedman, C. | D'Souza, A. | Bello Roufai, D. | +16

9

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer

enthalten in: Cancer | 2024

von Mutch, D. | Voulgari, A. | Chen, X. | +11

10

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc) : a randomised, open-label, phase 3 trial

enthalten in: Lancet (London, England) | 2024

von Oaknin, A. | Gladieff, L. | Martínez-García, J. | +117

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[17]